Furrukh Muhammad, Qureshi Asim
Department of Radiation Oncology, SHIFA International Hospital, Islamabad, Pakistan.
Department of Pathology, Sultan Qaboos University Hospital, Muscat, Sultanate of Oman.
J Ayub Med Coll Abbottabad. 2018 Apr-Jun;30(2):264-274.
Cancer of the breast is the leading female cancer accounting for one fourth of the malignancies. The tumour remains the most researched, read and practiced upon around the Globe. The treatment has substantially improved breast cancer related outcomes, both for early as well as late stages with substantial improvements in disease free and overall survival. Therapeutic decisions not only rest on clinical & tumour characteristics, but also with the evolution of molecular biology and tissue microarray intrinsic sub-types have been found. Attempts are being made to translate therapy from genomic architecture of individual breast cancer. This facilitates customization of treatment avoiding un-necessary toxicity, costs and inconvenience. Optimizing treatment based on individual breast biology seems logical and allows unifying treatment. The paper reviews literature, incorporate updates and also describes immunohistochemistry based molecular classification: which are found simple to adapt, record, present and subsequently manage, summarizing clinical practices in management of these patients.
乳腺癌是最主要的女性癌症，占恶性肿瘤的四分之一。该肿瘤仍然是全球研究、阅读和实践最多的。治疗方法已显著改善了乳腺癌相关的预后，无论是早期还是晚期，无病生存期和总生存期都有显著提高。治疗决策不仅取决于临床和肿瘤特征，还与分子生物学的发展有关，并且已经发现了组织微阵列内在亚型。人们正在尝试根据个体乳腺癌的基因组结构来调整治疗方案。这有助于定制治疗方案，避免不必要的毒性、成本和不便。基于个体乳腺生物学优化治疗似乎是合理的，并且能够实现治疗的统一。本文回顾了文献，纳入了最新进展，并描述了基于免疫组织化学的分子分类：这些分类易于采用、记录、呈现及后续管理，总结了这些患者管理中的临床实践。
